ライフサイエンスコーパス: folate receptor

1 re known to express high levels of the alpha-folate receptor).

2 ylphosphatidylinositol-anchored protein (the folate receptor).

3 y GPI-anchored proteins (5' nucleotidase and folate receptor).

4 and an assay was designed for screening the folate receptor.

5 nanosensors with cancer cells expressing the folate receptor.

6 t to target tumor cells that overexpress the folate receptor.

7 cells were transfected with the GPI-anchored folate receptor.

8 in cultured tumor cells that overexpress the folate receptor.

9 selectively taken up by tumor cells via the folate receptor.

10 r the imaging of tumors that overexpress the folate receptor.

11 ecific killing of cells that overexpress the folate receptor.

12 idant to renal proximal tubule cells via the folate receptor.

13 folates, the reduced folate carrier and the folate receptors.

14 such a paclitaxel (PTX) prodrug that targets folate receptors.

15 G alpha4 subunit in mediating responses from folate receptors.

16 tive delivery to cancer cells overexpressing folate receptors.

17 not be related to the very low expression of folate receptors.

18 ne delivery to cancer cells that overexpress folate receptors.

19 ED27 cells, and KB cells, which express the folate receptors.

20 from that of the reduced folate carrier and folate receptors.

21 harmaceutical for targeting tumor-associated folate receptors.

22 harmaceutical for targeting tumor-associated folate receptors.

23 derivatives, 5-methyltetrahydrofolate, from folate receptors.

24 lic acid as a drug-delivery system targeting folate receptors.

25 rigid ligand-binding site of these bona fide folate receptors.

26 ing targeting efficiency to cells expressing folate receptors.

27 e to the kidney and other tissues expressing folate receptors.

28 ake by the malignant cells that over-express folate-receptors.

29 Here we show that folate receptor 1 (FOLR1) is necessary for the formation

30 specificity for integrin alpha(4)beta(1) or folate receptor 1 (FOLR1), and common specificity for CD

31 nstrated its selectivity and potency against folate receptor 1 (FOLR1)-expressing ovarian cancer cell

32 njury-related induction of the high-affinity folate receptor 1 (Folr1).

33 We show that knockdown of folate receptor 1 (Folr1; also known as FRalpha) impairs

34 Here, we describe a protease-activated anti-folate receptor 1 TCB (Prot-FOLR1-TCB) equipped with an

35 in, tissue inhibitor of metalloproteinase 3, folate receptor 1, S100A2, signal transducer and activat

36 We show that the folate-receptor 1 (FolR1), a GPI-anchored cell surface m

37 othelial hyaluronan receptor 1(+)]/Folr2(+) [Folate receptor 2(+)]) and MHC2(+)(Major histocompatibil

38 Despite the isolation of placental folate receptors 25 y ago and progress in defining the m

39 Here we identify folate receptor 4 (Folr4) as the receptor for Izumo1 on

40 al antibodies against OX40, CTLA4, GITR, and folate receptor 4 (FR4).

41 nd instead caused those T cells to develop a Folate receptor 4(hi)CD73(hi) anergic phenotype.

42 ed markers of suppressive function (CD73 and folate receptor 4), and delayed disease after adoptive t

43 traits-including the expression of CD73 and folate receptor 4, and the epigenetic modification of Tr

44 (IMiD)-based molecular glues and PROTACs to folate receptor a (FOLR1)-positive cancer cells.

45 ynthase (hTS) and enter cancer cells through folate receptor a (FRa) highly expressed by several canc

46 tracellular distributions; some (such as the folate receptor) accumulate in transferrin-containing co

47 Recently, folate receptor alpha (FR alpha), a glycosylphosphatidyl

48 cosyl phosphatidylinositol-anchored protein, folate receptor alpha (FR alpha).

49 ) is an antibody-drug conjugate comprising a folate receptor alpha (FRa)-binding antibody, cleavable

50 In this work we examined the hypothesis that folate receptor alpha (FRalpha) acts as a transcription

51 Folate receptor alpha (FRalpha) autoantibodies have been

52 Folate receptor alpha (FRalpha) came into focus as an an

53 Folate receptor alpha (FRalpha) has been described as a

54 rug conjugate consisting of a humanized anti-folate receptor alpha (FRalpha) monoclonal antibody link

55 Folate receptor alpha (FRalpha) mRNA was shown by RT-PCR

56 t-in-class antibody-drug conjugate targeting folate receptor alpha (FRalpha), approved by the US Food

57 MOv18IgE, which targets folate receptor alpha (FRalpha), is a novel system to mo

58 or the three known folate transport proteins folate receptor alpha (FRalpha), proton-coupled folate t

59 -in-class IgE recognising the cancer antigen folate receptor alpha (FRalpha), showed preliminary sign

60 the reduced- folate transporter (RFT-1) and folate receptor alpha (FRalpha), the two proteins involv

61 OC, various ADCs targeting antigens such as folate receptor alpha (FRalpha), trophoblast cell surfac

62 A candidate antigen is the folate receptor alpha (FRalpha), which is overexpressed

63 oravtansine-gynx (MIRV) is a first-in-class, folate receptor alpha (FRalpha)-targeting antibody-drug

64 IRV) is an antibody-drug conjugate targeting folate receptor alpha (FRalpha).

65 d to induce Th17 responses to the OC antigen folate receptor alpha (FRalpha).

66 roton-coupled folate transporter (PCFT), and folate receptor alpha (FRalpha/Folr1), known to be regul

67 microscopy revealed the distribution of the folate receptor alpha along the basolateral region of th

68 eceptor alpha proteins, and suggest exosomal folate receptor alpha as a potential biomarker for early

69 y using MTX(R)-ZR-75-1 cells showed that the folate receptor alpha cDNA obtained by RT-PCR from the R

70 nt work represents the first analysis of the folate receptor alpha expression in intact mammalian ret

71 the reduced-folate transporter but also the folate receptor alpha in mediating this transport.

72 The expression of the folate receptor alpha in mouse RPE was analyzed by rever

73 In situ hybridization localized the folate receptor alpha mRNA to the mouse RPE cells and to

74 , and subsequent sequencing established that folate receptor alpha mRNA transcripts are expressed in

75 CD24, epithelial cell adhesion molecule and folate receptor alpha proteins, and suggest exosomal fol

76 n enhanced generation of high-avidity murine folate receptor alpha T cells that persisted in vivo and

77 Folate Receptor alpha Targeting Chimeras-dual (FolTAC-du

78 The folate receptor alpha was detected immunohistochemically

79 e present study was to determine whether the folate receptor alpha was present in the RPE and, if so,

80 A model epitope derived from the murine folate receptor alpha, a self- and tumor Ag, was modifie

81 essfully achieved targeted gene silencing in folate receptor alpha-expressing cancer cells.

82 FcgammaRIIIa was spatially associated with folate receptor alpha-positive (FRalpha+) tumor areas at

83 s specific for the cancer-associated antigen folate receptor alpha.

84 The human KB cell or alpha folate receptor (alpha hFR) is a membrane glycoprotein o

85 ive intracellular accumulation through alpha-folate receptor (alpha-FR) transport.

86 nhibitor specifically transported into alpha-folate receptor (alpha-FR)-overexpressing tumors.

87 A cDNA encoding the folate receptor-alpha (FR-alpha) was recovered from cell

88 chimeric antigen receptor (CAR) specific for folate receptor-alpha (FRalpha) have shown robust antitu

89 Children were subtyped by glutathione and folate receptor-alpha autoantibody (FRAA) status.

90 g of liposomes enhanced the sensitization of folate receptor-alpha(+) ovarian tumor cells in vitro, t

91 , specific for the tumour-associated antigen Folate Receptor-alpha, was well-tolerated and preliminar

92 ith tumours expressing the relevant antigen, folate receptor-alpha.

93 An mAb directed against the folate receptor also shifted approximately 50% of the ca

94 We now show by cell fractionation that folate receptors also must be clustered in caveolae for

95 llular uptake levels were independent of the folate receptor and did not require a pH-sensitive lipid

96 , nanoceria identified the expression of the folate receptor and EpCAM on lung carcinoma and breast a

97 pic cancer biomarkers at pH 7.0, such as the folate receptor and EpCAM.

98 unctionally by transfection the cloned human folate receptor and the human reduced-folate transporter

99 The expression of the folate receptor and the reduced-folate transporter in th

100 defect contains autoantibodies that bind to folate receptors and can block the cellular uptake of fo

101 tion between maternal autoantibodies against folate receptors and neural-tube defects reflects a caus

102 explain the high folate-binding affinity of folate receptors and provide a template for designing mo

103 r cell targeting and internalization via the folate receptor, and induces significant cancer cell dea

104 Folate receptors are one of three major types of folate

105 Folate receptors are overexpressed on activated macropha

106 Cell membrane-associated folate receptors are selectively overexpressed in certai

107 cid acted as both a targeting ligand for the folate receptor as well as a quencher for doxorubicin's

108 adenoviral infection of target cells via the folate receptor at a high efficiency.

109 rodevelopmental disorder typically caused by folate receptor autoantibodies (FRAs) that interfere wit

110 Additional studies of folate receptor autoimmunity and leucovorin calcium trea

111 monstrate that a subset of TAMs that express folate receptor B (FRB) possess an immunosuppressive M2-

112 Folate receptor beta (FR-beta) is present on activated m

113 Folate receptor beta (FR-beta), a marker expressed on ma

114 folate ((18)F-FOL) is a PET tracer targeting folate receptor beta (FR-beta), which is expressed on ac

115 uppressive population by its upregulation of folate receptor beta (FRB) within the TME and its restri

116 Folate receptor beta (FRbeta) is a myeloid-lineage antig

117 uppressive population by its upregulation of folate receptor beta (FRbeta) within the TME and its res

118 his tracer showed excellent targeting of the folate receptor beta on activated macrophages in synovia

119 ized in a receptor-specific manner into both folate receptor beta-expressing macrophage cell lines an

120 Activated macrophages express folate receptor-beta (FR-beta), which can be targeted by

121 FA-HSA-ATO could specifically recognize folate receptor-beta-positive (FRbeta+) chronic myeloid

122 folate receptors in mice, and knock-down of folate receptors by delivery of antisense oligonucleotid

123 To investigate the folate receptor dependence of gene transfer with the fil

124 h lipid to DNA ratios (e.g. 10 and 12), were folate receptor-dependent and required a pH-sensitive li

125 ion of murine breast cancer cells (4T1) in a folate receptor-dependent manner.

126 -rapa inhibited mTOR activity in a dose- and folate receptor-dependent manner.

127 xpressed at very low levels in most tissues, folate receptors, especially FRalpha, are expressed at h

128 se cells expressed very small amounts of the folate receptor evidenced from the binding of folate and

129 ogressed to clinical trials for detection of folate receptor-expressing gynecological tumors.

130 mediated potent and specific eradication of folate-receptor-expressing cancer cells in vitro and in

131 a portion of the excised specimens assessed folate receptor expression in 49 patients.

132 U appears to be a function of a cell's alpha-folate receptor expression.

133 d mice lacking Folbp2, another member of the folate receptor family that is GPI anchored but binds fo

134 eta, a GPI-anchored protein belonging to the folate receptor family.

135 behavior through a pathway that requires the folate receptor FOLR-1 and the GON-2 calcium channel.

136 methylation and with expression of both the folate receptor Folr1 and the de novo DNA methyltransfer

137 Finally, binding to the folate receptor (FOLR1) overexpressed in a cancer cell l

138 multiple forms of injury, we identified the folate receptor (FOLR1), highly expressed in both LTL-po

139 nclear how Juno - which was previously named folate receptor (FR) 4, based on sequence similarity con

140 carbon atoms) were synthesized as selective folate receptor (FR) alpha and beta substrates and as an

141 eyl pyrrolo[2,3-d]pyrimidines 2c and 2d with folate receptor (FR) alpha and proton-coupled folate tra

142 and 10-13 were selectively inhibitory toward folate receptor (FR) alpha-expressing Chinese hamster ov

143 ogue and potently inhibited proliferation of folate receptor (FR) alpha-expressing Chinese hamster ov

144 e system was characterized by detecting free folate receptor (FR) and an FR+ cancer cell line (KB) in

145 its distribution in the neighborhood of the folate receptor (FR) and beta-globin genes by using high

146 everal transporters and receptors, including folate receptor (FR) beta, a GPI-anchored protein belong

147 Folate receptor (FR) can be used as a therapeutic target

148 am to provide targeted antitumor agents with folate receptor (FR) cellular uptake specificity and gly

149 The folate receptor (FR) has proven a valuable target for nu

150 colorectal cancer cells based on folate (FA)/folate receptor (FR) interactions.

151 The folate receptor (FR) is a valuable therapeutic target th

152 Folate receptor (FR) is highly expressed in many types o

153 The membrane-bound high-affinity folate receptor (FR) is highly expressed on a wide range

154 the expression and functional competence of folate receptor (FR) isoforms on human hematopoietic cel

155 The glycosyl-phosphatidylinositol anchored folate receptor (FR) mediates selective delivery of a br

156 of targeted antifolates via their uptake by folate receptor (FR) proteins, resulting in inhibition o

157 different positions to folic acid (FA), the folate receptor (FR) targeting unit.

158 ted that a subset of macrophages expresses a folate receptor (FR) that can mediate internalization of

159 The folate receptor (FR) type alpha is a promising target fo

160 The folate receptor (FR) type alpha may be distinguished fro

161 phobic domain of the GPI signal in the human folate receptor (FR) type alpha was substituted with the

162 The utility of the folate receptor (FR) type alpha, in a broad range of tar

163 e characterized using a truncated version of folate receptor (FR) type beta (FR-beta delta 5) in whic

164 The folate receptor (FR) type beta is a promising target for

165 Folate receptor (FR) type beta is a promising target for

166 Folate receptor (FR) type beta is expressed in the myelo

167 When the GPI-anchored folate receptor (FR) type beta was expressed transiently

168 Up-regulation of folate receptor (FR) type-beta in acute myelogenous leuk

169 The homologous folate receptor (FR) types alpha and beta from both huma

170 Folate receptor (FR), a serum protein indicative of vari

171 cetylvinblastine conjugate that binds to the folate receptor (FR), which is expressed on the majority

172 tine hydrazide (DAVLBH), is a ligand for the folate receptor (FR), with activity against FR-positive

173 ement in the 5'-untranslated region of human folate receptor (FR)-alpha mRNA with a cytosolic trans-f

174 Repression of the folate receptor (FR)-alpha P4 core promoter by ER is enh

175 binding affinity assays were performed using folate receptor (FR)-alpha-expressing KB cells.

176 (99m)Tc, termed (99m)Tc-EC20, for imaging of folate receptor (FR)-expressing macrophages that accumul

177 CFT might play in another transport pathway, folate receptor (FR)-mediated endocytosis.

178 ly into the BALB/c athymic nude mice bearing folate receptor (FR)-overexpressing KB xenograft, the ta

179 ate FITC-specific CAR-T cell activity toward folate receptor (FR)-overexpressing tumor cells.

180 This agent was found to bind folate receptor (FR)-positive cells and tissues with hig

181 e DOTA-folate conjugate cm09, which binds to folate receptor (FR)-positive KB tumor cells.

182 f-PCN(DXR)) demonstrated enhanced potency to folate receptor (FR)-positive tumor cells such as KB and

183 epared a low-density lipoprotein (LDL)-based folate receptor (FR)-targeted agent by conjugating folic

184 EC131, a new folate receptor (FR)-targeted drug conjugate, was prepar

185 99mTc-EC20 is a folate receptor (FR)-targeted imaging agent consisting o

186 very and ultrasound-stimulated activation of folate receptor (FR)-targeted phase-change contrast agen

187 Folate receptor (FR)-targeted small molecule drug conjug

188 ting human cells that highly overexpress the folate receptor (FR).

189 orter/heme carrier protein 1 (PCFT/HCP1) and folate receptor (FR).

190 des and drugs into tumors overexpressing the folate receptor (FR).

191 third of human cancers that overexpress the folate receptor (FR).

192 0A and L1210JF) overexpress the cell surface folate receptor (FR).

193 t attached drugs to cells that overexpress a folate receptor (FR).

194 roton-coupled folate transporter (PCFT), and folate receptors (FR) are folate-specific transporters.

195 Folate receptors (FR) are inversely regulated by the ext

196 Glycosyl-phosphatidylinositol-anchored folate receptors (FR) have physiologic and pharmacologic

197 e through the translational up-regulation of folate receptors (FR) is unclear.

198 Folate receptors (FR) may be of use for targeted deliver

199 a 'database mining' strategy to detect novel folate receptors (FR), we identified two potential novel

200 The folate receptor (FRalpha) was significantly overexpresse

201 erated rat IgE and IgG mAbs specific for the folate receptor (FRalpha), which is expressed widely on

202 Folate receptors (FRalpha, FRbeta and FRgamma) are cyste

203 nese hamster ovary (CHO) sublines expressing folate receptors (FRs) alpha or beta (IC50s < 1 nM) or t

204 unds 1-3) were synthesized as substrates for folate receptors (FRs) and the proton-coupled folate tra

205 3b was completely selective for transport by folate receptors (FRs) and the proton-coupled folate tra

206 The expression of folate receptors (FRs) in cervical carcinoma (HeLa-IU1)

207 ellular acquisition of folate is mediated by folate receptors (FRs) in many malignant and normal huma

208 the intracellular trafficking of endocytosed folate receptors (FRs) labeled with fluorescent folate c

209 More recently, human folate receptors (FRs), high affinity receptors that tra

210 s study, the importance of sphingolipids for folate receptor function was investigated in Caco-2 cell

211 Our data suggest that the folate receptor gene and the beta-globin locus are regul

212 region between the beta-globin locus and the folate receptor gene is fully methylated and condensed a

213 ow that a 3.3 kbp DNA region upstream of the folate receptor gene is sufficient to induce strong expr

214 We have identified a folate receptor gene upstream of the chicken beta-globin

215 These include a folate receptor gene, a 16 kb condensed chromatin region

216 The human folate receptor (hFR) type gamma and gamma' are constitu

217 The human folate receptor (hFR) type gamma gene is driven by a TAT

218 The folate receptor homolog FOLR-1 is required for the stimu

219 t renal cyst-lining cells highly express the folate receptor in ADPKD and mouse models.

220 The involvement of the folate receptor in mediating tumor uptake of (111)In-DTP

221 n induction of expression of the human alpha folate receptor in nasopharyngeal epidermoid carcinoma c

222 Although a critical role of placental folate receptors in maternal-to-fetal folate transport w

223 Knockout of folate receptors in mice, and knock-down of folate recep

224 s study was to evaluate the in vivo assay of folate receptors in nonfunctional pituitary adenomas usi

225 ta-globin genes, consistent with the role of folate receptors in proliferation.

226 )Tc-folate is an accurate method of assaying folate receptors in vivo and may provide a quantitative

227 we hypothesized that autoantibodies against folate receptors in women may be associated with pregnan

228 Since antiserum to folate receptors induces embryo resorption and malformat

229 Our findings support a model in which the folate receptor interacts with cell adhesion molecules,

230 The cell membrane folate receptor is a potential molecular target for tumo

231 The cell-membrane folate receptor is a potential molecular target for tumo

232 The folate receptor is expressed at negligible levels in the

233 The folate receptor is overexpressed in a wide variety of hu

234 The folate receptor, like many glycosylphosphatidylinositol-

235 LM are taken up by activated macrophages via folate receptor mediated endocytosis and that their hydr

236 However, delivery of siRNA directly through folate receptor mediated endocytosis for gene silencing

237 asily internalized by cancer cells through a folate receptor-mediated endocytic pathway.

238 m of rapamycin (FC-rapa) that is taken up by folate receptor-mediated endocytosis and cleaved intrace

239 t can significantly facilitate "scale up" of folate receptor-mediated liposomal cancer therapy to the

240 nhibition of thymidylate synthase with alpha-folate receptor-mediated targeting of tumor cells.

241 ith the (111)In-1 complex, consistent with a folate receptor-mediated targeting process.

242 It is likely that folate receptor-mediated transport is not sufficient to

243 The folate receptor-mediated transport of 5-methyltetrahydro

244 The (111)In-DTPA-folate also shows folate receptor-mediated uptake and retention in the kid

245 The folate receptor-mediated uptake of 99mTc-HYNIC-folate by

246 t of sphingolipid depletion was specific for folate receptor-mediated vitamin uptake.

247 could effectively target cancer cells, where folate-receptor-mediated endocytosis of QDs into living

248 he vitamin B9-binding pocket of an ancestral folate receptor molecule.

249 arison with the uptake of these particles in folate-receptor-negative cell lines such as A549.

250 ed, suggesting a causal relationship between folate receptor number and vitamin uptake.

251 ttachment of folic acid ligand recognized by folate receptors of cancer cells is described).

252 presumably reflecting radiotracer binding to folate receptors of the proximal tubules.

253 ies blocked the binding of [3H]folic acid to folate receptors on placental membranes and on ED27 and

254 gent), folic acid (FA, targets overexpressed folate receptors on specific cancer cells), and methotre

255 JQ-FT is recognized by folate receptors on the plasma membrane and delivered in

256 ents and conjugated with tumor cells through folate receptors over-expressed on cancer cells.

257 ol subjects contained autoantibodies against folate receptors (P<0.001).

258 tidylinositol-anchored hydrophobic placental folate receptors (PFRs), which have an important functio

259 ex of 1 was found to selectively localize in folate receptor-positive human KB tumor xenografts and t

260 of nude mice bearing approximately 100 mm(3) folate receptor-positive human xenografts led to complet

261 ted following the treatment of an aggressive folate receptor-positive J6456 lymphoma model.

262 ly inoculated with approximately 1.8 x 10(6) folate receptor-positive KB (human nasopharyngeal carcin

263 (44)Sc-cm09 was investigated in vitro using folate receptor-positive KB tumor cells and in vivo by P

264 (47)Sc-labeled cm10 was tested on folate receptor-positive KB tumor cells in vitro.

265 ine (safety analysis set); 109 patients with folate receptor-positive ovarian cancer comprised the fu

266 57BL/6 mice bearing subcutaneously implanted folate receptor-positive syngeneic tumors.

267 rovide a quantitative marker for identifying folate receptor-positive tumors.

268 y of folic acid conjugated quantum dots into folate-receptor-positive cell lines such as KB cells.

269 neous inoculation of approximately 4 X 10(6) folate-receptor-positive KB (human nasopharyngeal carcin

270 glycosylphosphatidylinositol (GPI) anchored folate receptor protein alpha (FR alpha) and thereby can

271 The high affinity of folic acid for folate receptors provides a unique opportunity to use fo

272 ntibodies by incubation with human placental folate receptors radiolabeled with [3H]folic acid.

273 element separating the globin locus from the folate receptor region, which suggests that this insulat

274 leotides at gestation day 8 or antibodies to folate receptor, results in profound developmental abnor

275 In vitro (47)Sc-cm10 showed folate receptor-specific binding and uptake into KB tumo

276 r the whole time of investigation and showed folate receptor-specific binding to KB tumor cells.

277 f folate and from the detectable presence of folate receptor-specific transcript, but there was no ev

278 ed upon a combination of cell doubling time, folate receptor status, S phase percentage, and TSase ex

279 designing more specific drugs targeting the folate receptor system.

280 study model, we hypothesized that IMI with a folate receptor targeted near-infrared contrast agent (O

281 However, the potencies of all folate-receptor targeted therapies depend on 1) the rate

282 Folate receptor-targeted cancer therapies constitute a p

283 ary nodule were intravenously administered a folate receptor-targeted fluorescent contrast agent spec

284 onrandomized open-label trial of IMI using a folate receptor-targeted fluorescent tracer enrolled pat

285 t-inducible NF-kappaB downregulation through folate receptor-targeted hollow gold nanospheres carryin

286 Patients were preoperatively infused with a folate receptor-targeted near-infrared tracer.

287 mize both the potencies and specificities of folate receptor-targeted therapies in vivo.

288 Here we show that folate-receptor-targeted photosynthetic nanothylakoid (F

289 cally active agents covalently attached to a folate receptor targeting ligand unit via two disulfide-

290 To probe structural requirements for folate receptor targeting with low molecular weight radi

291 ere carried out to show that combined pH and folate-receptor targeting reduces off-target accumulatio

292 In this research, we have developed a folate receptor-targeting multifunctional dual drug-load

293 data does not support a contribution of the folate receptor to cytotoxicity.

294 alization of SWNTs inside cells labeled with folate receptor tumor markers, and NIR-triggered cell de

295 The folate receptor type alpha (FR-alpha) is a promising tum

296 a cell line overexpressing the tumor marker folate receptor, was affected by both the lipid to DNA r

297 To test this concept, we chose to target the folate receptor, which is overexpressed on the surface o

298 te 4-hydroxy-Tempo (tempol)-folate to target folate receptors, which are highly expressed in the prox

299 f ligand-mediated drug delivery by targeting folate receptors, which are overexpressed in most ovaria

300 Izumo1R is a pseudo-folate receptor with an essential role in mediating tigh